Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have earned a consensus rating of "Hold" from the six brokerages that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $7.00.

RXRX has been the topic of a number of analyst reports. Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Monday, June 16th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $4.83 on Tuesday. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The company's 50-day moving average price is $4.91 and its two-hundred day moving average price is $6.23. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The stock has a market cap of $1.96 billion, a PE ratio of -2.73 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter last year, the firm posted ($0.39) earnings per share. Recursion Pharmaceuticals's revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. Softbank Group CORP. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $99,152,000. Novo Holdings A S acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $68,375,000. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after buying an additional 9,737,196 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Recursion Pharmaceuticals by 183.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock valued at $33,901,000 after buying an additional 4,149,346 shares during the period. Finally, Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $23,429,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.